Literature DB >> 2935413

[3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors.

M L Porceddu, E Ongini, G Biggio.   

Abstract

Chronic treatment with SCH 23390, a selective D-1 dopamine receptor antagonist, increased (40%) the density of [3H]SCH 23390 binding sites in striatal membrane preparations but failed to change the apparent KD of the ligand for its binding sites. Haloperidol, which preferentially blocks D-2 receptors, induced only a slight, not significant increase in the total number of [3H]SCH 23390 binding sites. (-)Sulpiride, a selective D-2 receptor blocker, also failed to change either Bmax or KD of [3H]SCH 23390 binding. Thus, chronic blockade of D-1 receptor sites by SCH 23390 can lead to an increase in their total number.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935413     DOI: 10.1016/0014-2999(85)90151-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.

Authors:  S A Parashos; C Marin; P Barone; V Kapitzoglou-Logothetis; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

3.  Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors.

Authors:  C Marin; T M Engber; P Chaudhuri; A Peppe; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.

Authors:  D Lévesque; M P Martres; J Diaz; N Griffon; C H Lammers; P Sokoloff; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine.

Authors:  A Campbell; R J Baldessarini; J L Neumeyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390.

Authors:  A Vaccheri; R Dall'Olio; O Gandolfi; P Roncada; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390.

Authors:  G Serra; M Collu; G L Gessa
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function.

Authors:  S C Cheetham; C J Kettle; K F Martin; D J Heal
Journal:  J Neural Transm Gen Sect       Date:  1995

10.  Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity.

Authors:  J Luthman; E Lindqvist; D Young; R Cowburn
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.